Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Blood blood.2022019306.

https://doi.org/10.1182/blood.2022019306

Published: 2024

Includes: Supplemental data

Journal Articles

Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML

Sophie C James, Samantha Atkinson, Richard Burt, Cristina Lo Celso, Paolo Gallipoli

Blood (2024) 144 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2024-205582

Published: 2024

Journal Articles

Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Blood (2024) 144 (Supplement 1): 722.

https://doi.org/10.1182/blood-2024-202515

Published: 2024

Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Blood (2024) 143 (4): 336–341.

https://doi.org/10.1182/blood.2023021579

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen

Blood (2023) 142 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2023-181937

Published: 2023

Journal Articles

Real-World Experience of Asciminib: Factors Associated with Response

Blood (2022) 140 (Supplement 1): 6796–6797.

https://doi.org/10.1182/blood-2022-165501

Published: 2022

Journal Articles

Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3058–3060.

https://doi.org/10.1182/blood-2022-166811

Published: 2022

Journal Articles

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Blood (2022) 140 (Supplement 1): 2033–2035.

https://doi.org/10.1182/blood-2022-159467

Published: 2022

Journal Articles

Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML

Hannah Lawson, James Holt-Martyn, Vilma Dembitz, Jozef Durko, Yuka Kabayama, Lydia Wang, Louie Van De Lagemaat, Louis Dubusse, Laura Alunno, Amelie Guitart, Jürg Schwaller, Paolo Gallipoli, Dónal O'Carroll, Christopher Schofield, Kamil Kranc

Blood (2022) 140 (Supplement 1): 8731–8732.

https://doi.org/10.1182/blood-2022-165192

Published: 2022

Journal Articles

AML gets upSET when its dietary needs are unMet

Paolo Gallipoli

Blood (2022) 140 (19): 2003–2004.

https://doi.org/10.1182/blood.2022018008

Published: 2022

Journal Articles

Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia

Keith Woodley, Laura S Dillingh, George Giotopoulos, Pedro Madrigal, Konstantinos Tzelepis, Celine Philippe, Kevin Rattigan, Ryan Asby, Vilma Dembitz, Aoife S.M. Magee, Gudmundur Helgason, Kevin Rouault-Pierre, George S. Vassiliou, Brian J.P Huntly, Paolo Gallipoli

Blood (2021) 138 (Supplement 1): 508.

https://doi.org/10.1182/blood-2021-148489

Published: 2021

Journal Articles

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

Blood (2021) 138 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2021-149685

Published: 2021

Journal Articles

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Blood (2021) 138 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2021-150169

Published: 2021

Journal Articles

Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia

Syed Mian, Celine Philippe, Eleni Maniati, Tiffany Bergot, Marion Piganeau, Doriana Di Bella, Valle Morales, Andrew Finch, Katiuscia Bianchi, Jun Wang, Paolo Gallipoli, Uwe Platzbecker, Daniel H Wiseman, Dominique Bonnet, Delphine Bernard, John Gribben, Kevin Rouault-Pierre

Blood (2021) 138 (Supplement 1): 324.

https://doi.org/10.1182/blood-2021-147726

Published: 2021

Journal Articles

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies

Daniel Sasca, Haiyang Yun, George Giotopoulos, Jakub Szybinski, Theo Evan, Nicola K. Wilson, Moritz Gerstung, Paolo Gallipoli, Anthony R. Green, Robert Hills, Nigel Russell, Cameron S. Osborne, Elli Papaemmanuil, Berthold Göttgens, Peter Campbell, Brian J. P. Huntly

Blood (2019) 134 (24): 2195–2208.

https://doi.org/10.1182/blood.2019001553

Published: 2019

Includes: Supplemental data

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction

Haiyang Yun, PhD, Shabana Vohra, PhD, Annalisa Mupo, PhD, George Giotopoulos, PhD, Daniel Sasca, MD, Sarah J. Horton, PhD, Shuchi Agrawal-Singh, PhD, Eshwar Meduri, PhD, Faisal Basheer, MBBChir, MA, PhD, Ludovica Marando, Malgorzata Gozdecka, PhD, Oliver M. Dovey, PhD, Xiaonan Wang, PhD, Paolo Gallipoli, PhD, Cameron Osborne, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath

Blood (2019) 134 (Supplement_1): 278.

https://doi.org/10.1182/blood-2019-122413

Published: 2019

Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Blood (2018) 132 (Supplement 1): 1682.

https://doi.org/10.1182/blood-2018-99-117089

Published: 2018

Journal Articles

Glutaminolysis is a metabolic dependency in FLT3 ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition

Paolo Gallipoli, George Giotopoulos, Konstantinos Tzelepis, Ana S. H. Costa, Shabana Vohra, Paula Medina-Perez, Faisal Basheer, Ludovica Marando, Lorena Di Lisio, Joao M. L. Dias, Haiyang Yun, Daniel Sasca, Sarah J. Horton, George Vassiliou, Christian Frezza, Brian J. P. Huntly

Blood (2018) 131 (15): 1639–1653.

https://doi.org/10.1182/blood-2017-12-820035

Published: 2018

Includes: Supplemental data

Journal Articles

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Anuradha Tarafdar, Lisa E. M. Hopcroft, Paolo Gallipoli, Francesca Pellicano, Jennifer Cassels, Alan Hair, Koorosh Korfi, Heather G. Jørgensen, David Vetrie, Tessa L. Holyoake, Alison M. Michie

Blood (2017) 129 (2): 199–208.

https://doi.org/10.1182/blood-2016-09-742049

Published: 2017

Includes: Supplemental data

NARROW

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML

Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Real-World Experience of Asciminib: Factors Associated with Response

Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML

AML gets upSET when its dietary needs are unMet

Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service

Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Glutaminolysis is a metabolic dependency in FLT3 ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only